MX2020013883A - Tratamientos oncológicos con agentes de zinc. - Google Patents

Tratamientos oncológicos con agentes de zinc.

Info

Publication number
MX2020013883A
MX2020013883A MX2020013883A MX2020013883A MX2020013883A MX 2020013883 A MX2020013883 A MX 2020013883A MX 2020013883 A MX2020013883 A MX 2020013883A MX 2020013883 A MX2020013883 A MX 2020013883A MX 2020013883 A MX2020013883 A MX 2020013883A
Authority
MX
Mexico
Prior art keywords
methods
agent
treating
cancer patient
oncology treatments
Prior art date
Application number
MX2020013883A
Other languages
English (en)
Inventor
Jinhyuk Fred Chung
Original Assignee
Xylonix Ip Holdings Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG10201805412TA external-priority patent/SG10201805412TA/en
Priority claimed from SG10201811577TA external-priority patent/SG10201811577TA/en
Application filed by Xylonix Ip Holdings Pte Ltd filed Critical Xylonix Ip Holdings Pte Ltd
Publication of MX2020013883A publication Critical patent/MX2020013883A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a métodos para tratar a un paciente con cáncer que comprenden la administración de un agente de Zn(II) o una combinación de agente de Zn(II)/agente inmuno-oncológico para proporcionar un beneficio terapéutico al paciente con cáncer. Los métodos son útiles para tratar un amplio espectro de cánceres humanos, incluyendo tumores sólidos y células cancerosas de origen sanguíneo. En modalidades particulares, los métodos de tratamiento están dirigidos a tipos de cáncer caracterizados por mutaciones de inestabilidad genética.
MX2020013883A 2018-06-22 2019-06-21 Tratamientos oncológicos con agentes de zinc. MX2020013883A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201805412TA SG10201805412TA (en) 2018-06-22 2018-06-22 Zinc agents for monotherapy and combination therapy oncology treatments
SG10201811577TA SG10201811577TA (en) 2018-12-24 2018-12-24 Oncology treatments using zinc agents
PCT/SG2019/050308 WO2019245458A1 (en) 2018-06-22 2019-06-21 Oncology treatments using zinc agents

Publications (1)

Publication Number Publication Date
MX2020013883A true MX2020013883A (es) 2021-05-27

Family

ID=67108114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013883A MX2020013883A (es) 2018-06-22 2019-06-21 Tratamientos oncológicos con agentes de zinc.

Country Status (10)

Country Link
US (1) US20210128609A1 (es)
EP (1) EP3810154A1 (es)
JP (1) JP2021527707A (es)
KR (1) KR20210024065A (es)
CN (1) CN112584842A (es)
AU (1) AU2019290345A1 (es)
CA (1) CA3104612A1 (es)
MX (1) MX2020013883A (es)
SG (1) SG11202012373YA (es)
WO (1) WO2019245458A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
CA3214081A1 (en) * 2021-03-18 2022-09-22 Xylonix Pte. Ltd Pharmaceutical polymer conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010526917A (ja) 2007-05-09 2010-08-05 日東電工株式会社 複数種の薬物を有するポリグルタミン酸塩複合体及びポリグルタミン酸塩−アミノ酸複合体
WO2014155142A1 (en) 2013-03-28 2014-10-02 Bbs Nanotechnology Ltd. Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
WO2014175898A1 (en) 2013-04-26 2014-10-30 Nitto Denko Corporation A large scale process for preparing poly (glutamyl-glutamate) conjugates
US20200330557A1 (en) * 2016-08-19 2020-10-22 Brooklyn Immunotherapeutics Llc Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
SG10201609131YA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer

Also Published As

Publication number Publication date
KR20210024065A (ko) 2021-03-04
CA3104612A1 (en) 2019-12-26
WO2019245458A1 (en) 2019-12-26
EP3810154A1 (en) 2021-04-28
AU2019290345A1 (en) 2021-01-07
JP2021527707A (ja) 2021-10-14
CN112584842A (zh) 2021-03-30
US20210128609A1 (en) 2021-05-06
SG11202012373YA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
PH12020551908A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
EP4324460A3 (en) Sodium bicarbonate for use in the treatment of gout and related disorders
TW201613589A (en) Combination methods for treating cancers
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
MX2020001727A (es) Terapia de combinacion.
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2021008972A (es) Terapia de combinacion de quelante metalico para el tratamiento del cancer.
MX2020013883A (es) Tratamientos oncológicos con agentes de zinc.
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
WO2020005172A3 (en) Near-infrared (nir) absorbing photosensitizers
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2020004960A (es) Asociacion de activos para tratar el cancer de prostata.
IL177953A0 (en) Combination therapy including azd2171 and a taxane
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
WO2008144659A3 (en) Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
MX2019014842A (es) Uso de una combinación de ivosidenib y radiación para tratar gliomas.
MX2023005314A (es) Composiciones de nanoparticulas para tratamiento de cancer.
MX2019014934A (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
Abratt The fast neutron therapy programme for patients in South Africa should come to an end: correspondence